Spectral Diagnostics Inc. signed an exclusive option agreementwith The Johns Hopkins University School of Medicine ofBaltimore for exclusive licensing of cDNA clones coding forhuman cardiac Troponin I.
The agreement was made in preparation for the Torontocompany's second generation of cardiac prognosis tests. Duringthe option period, Spectral Diagnostics (NASDAQ:DIAGF) willevaluate the suitability of the clones for use in manufacturingof scale-up quanities of recombinant Troponin I. Using this andother markers should allow the company to produce cardiacprognostics "in which the efficacy of treatments for cardiacailments can be measured more accurately than has beenpossible in the past."
(c) 1997 American Health Consultants. All rights reserved.